IL2 and colorectal carcinoma: Data from another RCT, where 30 obese individuals were randomized to receive 1 g/day CRC or placebo, showed that CRC significantly reduced IL-1β, IL-4, and VEGF serum levels, but no significant differences were observed for IL-2, IL-6, IL-8, IL-10, IFN-γ, epidermal growth factor, and monocyte chemoattractant protein-1 levels [98].